The popularity of Viagra initially sparked a boom for major pharmaceutical companies, but recent shifts present a murky scenario for investors. Off-patent versions are eroding revenue, and ongoing patent challenges add https://marleypfaz048310.blogolenta.com/38223455/the-blue-pill-and-big-pharma-a-volatile-investment